CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 69 enrolled
Drug / intervention
Anti-GD2 3F8 Monoclonal Antibody +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02100930
NCT02100930N/ACompleted
CompareCT.gov

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 1, 2014·Updated Feb 28, 2020

In Brief

A clinical study evaluating Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor), and 1 other intervention for Neuroblastoma. Completed, enrolled 69 participants across 1 site.

Detailed Summary

The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroblastoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 1, 2014
Enrollment StartMar 1, 2014
Primary CompletionMar 7, 2019
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 12.3 years ago

Interventions

Anti-GD2 3F8 Monoclonal Antibodybiological

GM-CSF (granulocyte-macrophage colony-stimulating factor)drug

oral isotretinoindrug